In the latest session, Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $1.07 down -5.31% from its previous closing price of $1.13. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 2412981 shares were traded.
Ratios:
For a deeper understanding of Sangamo Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.04 and its Current Ratio is at 3.04. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on November 03, 2023, Downgraded its rating to Sector Perform and sets its target price to $2 from $6 previously.
On April 28, 2023, BofA Securities Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $5 to $1.50.
Wedbush Upgraded its Neutral to Outperform on February 27, 2023, while the target price for the stock was maintained at $16.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 26 when BIOGEN INC. sold 6,000,000 shares for $0.50 per share. The transaction valued at 3,000,000 led to the insider holds 17,652,466 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 189.76M and an Enterprise Value of 92.63M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.94 while its Price-to-Book (P/B) ratio in mrq is 1.41. Its current Enterprise Value per Revenue stands at 0.46 whereas that against EBITDA is -1.05.
Stock Price History:
Over the past 52 weeks, SGMO has reached a high of $3.16, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is 0.6042, while the 200-Day Moving Average is calculated to be 0.8264.
Shares Statistics:
For the past three months, SGMO has traded an average of 2.10M shares per day and 4.53M over the past ten days. A total of 166.79M shares are outstanding, with a floating share count of 157.22M. Insiders hold about 11.35% of the company’s shares, while institutions hold 49.38% stake in the company. Shares short for SGMO as of Feb 15, 2024 were 9.73M with a Short Ratio of 4.64, compared to 9.16M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.48% and a Short% of Float of 6.39%.
Earnings Estimates
There are 9 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.26 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.37, while EPS last year was -$0.32. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.06 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$1.3 and -$1.51 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$0.48, with 9 analysts recommending between -$0.3 and -$0.84.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $8.1M this quarter.It ranges from a high estimate of $16.44M to a low estimate of $3.4M. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $27.23M, an estimated decrease of -70.30% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $7.16M, a decrease of -95.50% less than the figure of -$70.30% in the same quarter last year. There is a high estimate of $11.23M for the next quarter, whereas the lowest estimate is $3.4M.
A total of 9 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $190.63M, while the lowest revenue estimate was $177.6M, resulting in an average revenue estimate of $183M. In the same quarter a year ago, actual revenue was $111.3M, up 64.40% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $53.13M in the next fiscal year. The high estimate is $138M and the low estimate is $13.8M. The average revenue growth estimate for next year is down -71.00% from the average revenue estimate for this year.
